• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » AltheaDx launches drug development oncology panel

AltheaDx launches drug development oncology panel

December 3, 2015
CenterWatch Staff

AltheaDx, a San Diego-based commercial stage molecular diagnostics company, has launched a CLIA-validated, next-generation sequencing (NGS) assay, AltheaDx Oncology Panel (AOP50), designed for multiple drug and companion diagnostic development programs.

Based on Thermo Fisher Scientific’s Oncomine Focus Assay, the AOP50 Assay allows concurrent analysis of DNA and RNA from solid tumors, enabling sequencing of 35 hotspot genes and 23 fusion genes in a single workflow on the Ion PGM System. With the increasing importance of genetic translocations in oncology, the AOP50 Assay also enables gene fusion transcript detection and reduces the complexity of performing alternate fusion detection methods such as fluorescence in situ hybridization (FISH).

Leveraging the low-sample input requirement from formalin-fixed paraffin-embedded (FFPE) tissue (10ng extracted nucleic acid for a total of 20ng per sample) of the Ion AmpliSeq technology, AOP50 enables accurate and reliable analysis of sequences from different tumor sample types, including small biopsies and fine needle aspirates.

“We are excited to add AOP50 to our growing portfolio of services. These tools will continue to enable clinical research efforts crucial to improving patient care and therapeutic decision-making for oncology professionals in the future,” said Jorge Garces, president and chief operating officer of AltheaDx.

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing